Spevatamig

N/A

Report date: 2025/09/25 17:33:10

Base Information

Drug NameSpevatamig
Drug Alias NameAnti-claudin18.2/anti-CD47 bispecific antibody (Phanes Therapeutics)PT886PT-886PT886
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionClaudin-18 splice variant 2 antagonistsCluster of differentiation 47 inhibitors
TargetsClaudin-18 splice variant 2Cluster of differentiation 47
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPhanes Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFanenshi Pharmaceutical (Beijing) Co LtdPhanes Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A